MDR1 Expression in Osteosarcomas
Author Information
Author(s): PD Lee, SE Noble-Topham, RS Bell, IL Andrulis
Primary Institution: University of Toronto
Hypothesis
Does MDR1 mRNA expression in osteosarcomas vary with location within the tumour, following chemotherapy, or after metastasis?
Conclusion
MDR1 expression levels in osteosarcomas do not vary greatly with location, chemotherapy, or metastasis, suggesting some tumours may be intrinsically resistant to doxorubicin.
Supporting Evidence
- Specimens from multiple locations in six tumours showed little variation in MDR1 expression.
- In 16 of 20 cases, MDR1 levels did not change appreciably after chemotherapy.
- Eight of ten specimens before and after metastasis showed constant MDR1 mRNA levels.
Takeaway
This study looked at how a gene related to drug resistance behaves in bone cancer. It found that the levels of this gene don't change much even after treatment.
Methodology
The study used a modified RT-PCR assay to measure MDR1 mRNA levels in osteosarcoma specimens collected from various locations and at different treatment stages.
Limitations
The study did not establish a direct correlation between MDR1 expression levels and chemotherapy response.
Participant Demographics
All patients presented free of metastatic disease and received neoadjuvant chemotherapy including doxorubicin.
Statistical Information
P-Value
0.07
Statistical Significance
p=0.07
Want to read the original?
Access the complete publication on the publisher's website